China Construction Bank

Seven deals launched Thursday as issuers came out in force to raise money ahead what is expected to be greater market uncertainty in November.

China’s domestic bond market is poised for another landmark transaction with Standard Chartered Bank (Hong Kong) opening books to a special drawing rights-denominated bond on Tuesday.

China Resources Pharmaceutical Group priced its Hong Kong IPO near the middle of expectations on Friday morning, raising HK$14bn ($1.8bn) after investors stormed into the trade.

Standard Chartered Bank (Hong Kong) has unveiled the syndicate for its special drawing rights-denominated bond.

China Resources Pharmaceutical Group has tightened the price range on its IPO, putting it on track to raise up to HK$14.8bn ($1.9bn), according to a banker on the deal.

China Resources Pharmaceutical Group is proving a hit with global investors, as its HK$15.7bn ($2.0bn) Hong Kong IPO is heavily oversubscribed, according to a banker at one of the leads.

China Resources Pharmaceutical Group’s HK$15.7bn ($2.0bn) Hong Kong IPO got off to a flying start this week, with books covered and support from high profile cornerstone investors giving it momentum.

China Resources Pharmaceutical Group has lined up eight cornerstone investors for its HK$15.6bn ($2.0bn) Hong Kong IPO, with the group agreeing to buy $916m worth of shares.

Some eight banks that arranged Saudi Arabia’s $10bn loan in May have secured berths on the sovereign's bond extravaganza that is due to kick off this week.

China Resources Pharmaceutical Group will raise as much as HK$15.6bn ($2.0bn) via a Hong Kong IPO after firming up the price range.

Shandong International Trust Co has submitted an IPO application to the Hong Kong Stock Exchange for an expected $300m offering.

It has been a busy period for the structured finance community in China with three lenders securitizing a combined Rmb3.28bn ($491m) worth of non-performing loans (NPLs) in the space of a week.